Modernavs.Regeneron
MRNA vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 2.6× larger than Moderna by market cap; year to date, Moderna leads (+131.5% vs −13.9%).
Side by side
| MRNA | REGN | |
|---|---|---|
| Market cap | $27.2B | $69.7B |
| Price | $68.27 | $664.52 |
| Today | −10.8% | −0.5% |
| Return YTD | +131.5% | −13.9% |
| Return 1Y | +99.2% | +18.7% |
| P/E | — | 15.7 |
| P/S | 12.2 | 4.7 |
| P/B | 3.7 | 2.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
ModernaMRNA
American biotech company based on mRNA technology — known for the covid vaccine, with a pipeline in vaccines and oncology.
Full MRNA profile →RegeneronREGN
American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.
Full REGN profile →More comparisons in Biotech & innovation
See where MRNA and REGN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →